Comparing 1.1 mm Cryoprobe and Biopsy Forceps for Diagnosing Lung Transplant Rejection

What this Trial Is About

Researchers are evaluating which biopsy collection method, a 1.1 mm cryoprobe or biopsy forceps, better helps diagnose rejection and other important tissue findings in lung transplant recipients. This randomized clinical trial aims to compare the quality and diagnostic value of lung tissue samples obtained by these two methods to improve detection of transplant rejection. Participants will be randomly assigned to receive lung tissue samples either by the cryoprobe, which uses rapid freezing to remove small tissue fragments, or by biopsy forceps, the current standard method that may cause more tissue damage. The cryoprobe collects three biopsies from two different lung lobes, and forceps collect 10-12 biopsies using a disposable device. The study compares sample quality, the amount of tissue collected, and the time required for each method. Participants will undergo biopsy during their scheduled bronchoscopy for lung transplant surveillance and be monitored for any adverse events for up to 30 days after the procedure. Researchers will assess tissue quality, diagnostic yield, sample adequacy, and procedural time to determine which biopsy method provides better results for detecting lung transplant rejection. The trial lasts from the time of biopsy through one month of follow-up.

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients